ReviewCurrent opinion in pulmonary medicine2018
Methamphetamine and the risk of pulmonary arterial hypertension.
Review in Current opinion in pulmonary medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Expert Consensus to Explore the Definition and Characterization of Methamphetamine-Associated Pulmonary Arterial Hypertension and Key Treatment Considerations.CHEST pulmonary · 2026Article
- Exposure Pattern Determines Methamphetamine-Induced Right Ventricular Dysfunction and Vascular Remodeling.Comprehensive Physiology · 2026Article
- Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management.Pulmonary circulation · 2026Review
- 4,4'-DMARFrontiers in cardiovascular medicine · 2026Article
- Methamphetamine-Associated Pulmonary Arterial Hypertension Is Associated With Worse Right Ventricular Function Than Idiopathic Pulmonary Arterial Hypertension: A Matched Study.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- Pulmonary Complications of Substance Abuse: Pathophysiology, Diagnosis, and Management Strategies.Addiction & health · 2025Review
- Severe Cardiopulmonary Complications and Stroke in a Patient With HIV and Chronic Substance Abuse: A Case Report.Cureus · 2024Article
- Nupr1-mediated vascular smooth muscle cell phenotype transformation involved in methamphetamine induces pulmonary hypertension.Cell biology and toxicology · 2024Article
- Radiation to Illuminate the Path of Neuromodulation for Pulmonary Hypertension.JACC. Basic to translational science · 2024Article
- Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study.Frontiers in cardiovascular medicine · 2024Article
- Cases of Phenotypic Switching From Dilated Cardiomyopathy to Pulmonary Arterial Hypertension in Chronic Methamphetamine Users.JACC. Advances · 2023Article
- HIV and Drug Use: A Tale of Synergy in Pulmonary Vascular Disease Development.Comprehensive Physiology · 2023Article
- Drugs of Misuse: Focus on Vascular Dysfunction.The Canadian journal of cardiology · 2022Review
- An adult case of NOTCH3 mutation in pulmonary artery hypertension.Pulmonary circulation · 2022Article
- Effects of moderate-intensity exercise on social health and physical and mental health of methamphetamine-dependent individuals: A randomized controlled trial.Frontiers in psychiatry · 2022Article
- Shortened leukocyte telomere length in young adults who use methamphetamine.Translational psychiatry · 2021Article
- Cor Pulmonale from Concomitant Human Immunodeficiency Virus Infection and Methamphetamine Use.CASE (Philadelphia, Pa.) · 2021Article
- Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.Comprehensive Physiology · 2021Article
- Sex-dependent right ventricular hypertrophic gene changes after methamphetamine treatment in mice.European journal of pharmacology · 2021Article
- The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review.Journal of internal medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewMethamphetamine is a highly addictive drug originally developed for the treatment of neuropsychiatric disorders. At present, the epidemic rise of illicit methamphetamine use has increased the number of patients living with medical complications. Our group has recently identified a definite association between methamphetamine use and pulmonary arterial hypertension (PAH), a life-threatening disease characterized by occlusive vasculopathy and progressive right heart failure. This review will discuss the evidence that links methamphetamine with PAH and how to approach the diagnosis and management of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) patients in clinic. RECENT
findingsCompared with idiopathic (I) PAH, Meth-APAH patients present with worse functional status, right ventricular dysfunction, and exercise tolerance. Despite therapy, the 5-year survival of Meth-APAH patients is significantly lower compared with IPAH. Genetic studies suggest that loss of function variants in genes involved in drug detoxification can increase susceptibility for methamphetamine-related vascular injury and trigger occlusive vasculopathy. SUMMARY: PAH patients undergoing diagnostic evaluation should be screened for a history of current or past methamphetamine use. Pharmacovigilance should be implemented to monitor patients being treated with methamphetamine for neuropsychiatric disorders (e.g., attention-deficit hyperactivity disorder). More studies will be needed to identify which susceptibility factors increase risk of PAH in methamphetamine users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.